Research Outputs

Now showing 1 - 2 of 2
Thumbnail Image
Publication

A computational study of the antioxidant power of eugenol compared to Vitamin C

2023, Rasul, Hezha, Aziz, Bakhtyar, Salgado-Morán, Guillermo, Mendoza-Huizar, Luis, Belhassan, Assia, Dra. Gerli-Candia, Lorena, Cardona-Villada, Wilson, Sadasivam, Kandasamy

The antioxidant power of eugenol and vitamin C was examined by analyzing the ability of these ligands to bind to the NADPH oxidase protein target and evaluating their bond interactions with critical residues. The results confirm that docked ligands are more stable in the specified active region of 2CDU during a MD simulation of 100 ns and 2CDU protein-ligand interactions with docked ligands showed significant hydrogen bond, hydrophobic, and water bridge formation. Eugenol exhibits hydrogen bond interactions with critical residues in the selective pocket in comparison to vitamin C. Also, eugenol had a similar binding orientation and very considerable stability in the selective pocket of 2CDU with a high binding energy with lipophilic energy. The electrostatic potential maps indicate that for eugenol, the –OH and –OCH3 sites, while that the –OH and –CO functional groups in vitamin C are responsible of the antioxidant activities of these compounds. HAT and SET mechanisms suggest that eugenol may become a better antioxidant than vitamin C.

Thumbnail Image
Publication

Theoretical investigation of the molecular structure and molecular docking of etoricoxib

2020, Dra. Gerli-Candia, Lorena, Sadasivam, Kandasamy, Salgado-Moran, Guillermo, Mendoza-Huizar, Luis Humberto, Cardona-Villada, Wilson, Meneses-Olmedo, Lorena Maribel, Cuesta-Hoyos, Sebastián

In this work, a computational chemical study of Etoricoxib was carried out at the X/6311G(d,p) (where X=B3LYP, M06 and B97XD) level of theory, at the gas, aqueous and ethanol phases. Through the chemical reactivity descriptors derived from the DFT, it was possible to find that Etoricoxib structure exhibits a major chemical activity in water and ethanol phases in comparison to the gas phase, which suggests this drug would be more active in biological solvents like in blood, tissues and places where the ciclooxigenasa 2 (COX)-2 is found. In addition, a molecular docking analysis was conducted to study the interaction of Etoricoxib with the COX-2 active site. The results suggest that Etoricoxib interacts with 19 amino acid residues inside the COX-2 active site.